OPTI-AML Challenges Fixed Venetoclax Shortening

Company Leukemia & Lymphoma Society (Beat AML) Event Type Published Research (Prospective Randomized Clinical Trial) Modality BCL-2 inhibitor plus hypomethylating agent, duration-randomized Asset Venetoclax plus azacitidine (14-day vs. 28-day schedule) Target BCL-2 Disease Area Newly diagnosed acute myeloid leukemia (AML) in older adults Summary The…